Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Palatin Technologies, Inc. (PTN)

4.22   0.01 (0.24%) 11-25 13:00
Open: 4.35 Pre. Close: 4.21
High: 4.35 Low: 4.12
Volume: 9,068 Market Cap: 44(M)

Technical analysis

as of: 2022-11-25 1:59:46 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6     One year: 6.83
Support: Support1: 3.99    Support2: 3.31
Resistance: Resistance1: 5.13    Resistance2: 5.84
Pivot: 4.39
Moving Average: MA(5): 4.22     MA(20): 4.59
MA(100): 5.9     MA(250): 8.44
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 14.8     %D(3): 13.9
RSI: RSI(14): 40.5
52-week: High: 17  Low: 0.27
Average Vol(K): 3-Month: 85 (K)  10-Days: 30 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTN ] has closed above bottom band by 32.0%. Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.22 - 4.24 4.24 - 4.26
Low: 3.97 - 3.99 3.99 - 4.01
Close: 4.18 - 4.21 4.21 - 4.24

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Headline News

Sat, 26 Nov 2022
U.P. Yoddhas vs Patna Pirates, Pro Kabaddi 2022 Season 9, LIVE Streaming details: When and where to watch U... - Zee News

Fri, 25 Nov 2022
Where Does Palatin Technologies, Inc. (PTN) Stock Fall in the Biotechnology Field After It Is Lower By -2.76% This Week? - InvestorsObserver

Thu, 24 Nov 2022
Seaport Res Ptn Weighs in on Bread Financial Holdings, Inc.'s FY2022 Earnings (NYSE:BFH) - MarketBeat

Wed, 23 Nov 2022
Helmerich & Payne, Inc. (NYSE:HP) Forecasted to Earn Q1 2023 Earnings of $0.83 Per Share - MarketBeat

Wed, 23 Nov 2022
Seaport Res Ptn Comments on Dominion Energy, Inc.'s FY2023 Earnings (NYSE:D) - MarketBeat

Tue, 22 Nov 2022
Duke Energy (NYSE:DUK) Downgraded by Seaport Res Ptn to "Sell" - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 231 (M)
% Held by Insiders 2.2711e+008 (%)
% Held by Institutions 4.3 (%)
Shares Short 4,770 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.22e+007
EPS Est Next Qtl 0
EPS Est This Year -0.35
EPS Est Next Year -0.06
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -12
Return on Assets (ttm) 429
Return on Equity (ttm) -25.1
Qtrly Rev. Growth 259440
Gross Profit (p.s.) 0
Sales Per Share -72.13
EBITDA (p.s.) -1.56e+007
Qtrly Earnings Growth -0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -33 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 18.87

Stock Dividends

Dividend 0
Forward Dividend 1.149e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.